Focused On-demand Library for Mitochondrial ribonuclease P catalytic subunit

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Mitochondrial ribonuclease P protein 3; Protein only RNase P catalytic subunit

Alternative UPACC:

O15091; B4DXD9; B4E0S8; B4E211; C4AM93; D3DS99; D3DSA1; Q86SZ4; Q86YB5; Q8N5L5


The Mitochondrial ribonuclease P catalytic subunit, also known as Protein only RNase P catalytic subunit, plays a pivotal role in mitochondrial RNA processing. It is a key component of the mitochondrial ribonuclease P complex, essential for cleaving tRNA molecules at their 5'-ends, a critical step in the maturation of mitochondrial tRNAs. This protein's function underscores its importance in mitochondrial transcription and translation, processes vital for cellular energy production.

Therapeutic significance:

Combined oxidative phosphorylation deficiency 54, a multisystem disorder with variable manifestations including sensorineural hearing loss and muscle weakness, is linked to mutations affecting this protein. Understanding the role of the Mitochondrial ribonuclease P catalytic subunit could open doors to potential therapeutic strategies for this and related mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.